
Eugene Braunwald MD
Adult Congenital Heart Disease
Hersey Distinguished Professor of the Theory and Practice of Physic, Brigham and Women's Hospital
Join to View Full Profile
75 Francis StBoston, MA 02115
Phone+1 617-732-7477
Fax+1 617-975-0955
Dr. Braunwald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Johns Hopkins UniversityResidency, Internal Medicine, 1957 - 1958
- SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1953 - 1954
- Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1952 - 1953
- New York University School of MedicineClass of 1952
Certifications & Licensure
- MA State Medical License 1972 - 2017
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 1974
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Elected Member The American Society for Clinical Investigation
Clinical Trials
- Thrombolysis in Myocardial Ischemia Trial (TIMI III) Start of enrollment: 1989 Apr 01
- Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome Start of enrollment: 2007 Feb 01
- Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study) Start of enrollment: 2008 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial.Karola S Jering, Brian L Claggett, Eugene Braunwald, Christopher B Granger, Lars Køber
Journal of Cardiac Failure. 2025-04-16 - 2 citationsAortic Valve Replacement for Asymptomatic Severe Aortic Stenosis-The Time Has Come.Brian R Lindman, Eugene Braunwald, Patricia A Pellikka
JAMA Cardiology. 2025-04-01 - Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases.Carolina Roselli, Ida Surakka, Morten S Olesen, Gardar Sveinbjornsson, Nicholas A Marston
Nature Genetics. 2025-03-01
Journal Articles
- Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionThomas A Gaziano, Gregg C Fonarow, Eugene Braunwald, JAMA Cardiology
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology
- Managing Stable Ischemic Heart DiseaseElliott M Antman, Eugene Braunwald, The New England Journal of Medicine
- Join now to see all
Lectures
- Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Fatal or Irreversible Bleeding and Ischemic Events with Rivaroxaban in Acute Coronary SyndromeHarvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 4/28/2013
Authored Content
- Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionAugust 2020
- Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionAugust 2020
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
- Treatment of HypertensionNovember 2018
- Rivaroxaban and Post-Stroke Neurological Outcomes in Patients with Acute Coronary SyndromeFebruary 2018
- Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
- Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
- Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
- Join now to see all
Press Mentions
- Verve Scores with One-Time Gene Editing Treatment for Heart DiseaseApril 15th, 2025
- Topline Data Point to Promise for VERVE-102 Gene-Editing TherapyApril 14th, 2025
- A Brave New World: Achieving Meaningful Progress in CardiologyMarch 30th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: